Member Info for shanny

thomasjones@tips.com

asDiamonEx is an Australian based company with listings on AIM, in Botswana and Australia which is shortly set to make the move from the ranks of the explorers to the smaller club of quoted producers. Operating in Botswana and the US, the flagship project is the Lerala mine in Botswana which, according to a statement published on May 29th, is set to commence production by 30th June this year and will be fully operational by the end of August 2008. The vast majority of our 18p per share valuation is derived from Lerala which we have valued using a conservative DCF based model and from the (less advanced but potentially larger) Sloan Kimberlite project in Colorado. At 12p we initiate our coverage with a stance of a speculative buy ........website www.diamonex.com.au

Hi Mary1955,im no expert myself but I think it is fairley common on AIM stocks to have a large spread,but more often than not its not quite as large as it is showing .Ive just run a test with halifax and on a ficticous 10000 share buy /.sell,spread was ..2.195 to buy cost £232.55.......1.7 to sell £172.36 inc costs,,but still approx 25% difference . Hope that helps.Think its something to be aware of before buying AIM stocks ,best of luck.

http://search.bbc.co.uk/cgi-bin/search/results.pl?uri=%2F&scope=all&go=toolbar&q=land+of+leather

Plenty of interest here ,nice to see some upward movement,

See ACG share news

May be speculation on yesterdays news that thyey are in advanced stages of disccusions with a third party over possible cash offer ,see second paragraph ,there was a small mention in this mornings press

see latest news

Morning Gedw,that should read Oct 2005,

HiGedw,Yes IQE is a share i also have interest in since Oct 2006 ,just came across this with the connection with IQE and found it of interest , but as you say it is a bit rich for penny share investor,but one I will be keeping an eye on.Nice to hear from you and once again I would like to thank you and the many others for the amount of research and information you contribute to this site,best wishes and have a good evening

Hi Chan /Gedw,I know you are fans of IQE ,thought you might like to take alook at ENF .Market leader in providing LED light engines and arrays for lighting systems,they have a consortium of companies in a £3.3m research project NoveLELS ,inc Airbus uk ,IQEplc,Systems div of GE Aviation,Augusta Westland,Mesophotonics,Exxelis Ltd, the University of Bath,and Brunel University.Also government supported.More information at WWW.Enfis.co.uk

The AGM is at 1-3 St James Gate 11.00am 27 July. Dermasalvescience.com (page 46)

High Chan , nice to see you back ,hope you are well .Thanks for the info I for one will be up on the roof .Have a good day

Hi Fourteenhundred,hope all is well,yes I think your right there must be something in the wind ,im sitting tight here and just waiting for the fun to start lol. Have a good day.

Hi Fourteenhundred,hope all is well,yes I think your right there must be something in the wind ,im sitting tight here and just waiting for the fun to start lol. Have a good day.

Hi Fourteenhundred,yes i've held these also for some time now and i'm quite happy with my lot,so at the moment i wont be adding.Present avg is 2.14.I hope you are having a good day

Libra Natural Resources, the company that acquires and invests in waste to energy assets, announced a placing raising 3.5 million pounds at 10p. The proceeds are expected to be used for working capital and should enable the company to exploit the increasing growth and investment opportunities within the company's wood pellet business. Specifically, the new monies raised will allow Libra to upgrade and develop its existing wood pellet facilities in Canada. The investment follows exceptional first quarter performance from the business. CEO, Peter Greensmith believes that the placing will enhance production and therefore earnings while allowing new institutional investors to take stakes in the company. Our valuation of Libra on a sum-of-the-parts basis (assuming is 31 million pounds or 18.3p per share. The calendar 2006 results will be published soon and should be accompanied by news of value realization in wood which may well prompt us to increase our target price. Ahead of the numbers, at 11.5p, our recommendation remains “buy”

Over the past eight weeks the market has slowly started to wake up to the potential of Mano River – a potential we flagged in a detailed note published on 8th June. Among the myriad of AIM listed juniors Mano is unusual in that it has a project - the New Liberty Gold Mine in Liberia -where a bankable feasibility study has been completed and where production is set to commence in 2008. So Mano can generate near term cashflow. Moreover Mano is believed to be working to realize value via a three way demerger of its iron, gold and diamonds interests and it has been suggested that at least two of those operations may well attract bid interest. The first operation which will be spun off (onto AIM) is Stellar Diamonds. On June 1st Mano announced its results for the year to January 31st 2007. Mano recorded a net loss of $953,545 as compared to a net loss of $1.34 million in 2006. Administrative overheads totalled $1,006,726 over the twelve month period, compared to $1,559,914 in 2006, the decrease being primarily due to lower professional fees. Revenue for the period came from interest earned from cash deposits, $53,181. As at 31st January 2007, the company had working capital of $1,005,543. We value the company’s assets on a sum of the parts basis. We believe Mano's shares are worth at least 20.5p a share and hence, at 12.55p our stance remains strong buy.

shares have drifted lower over the past month in the absence of any meaningful newsflow. The company offers a diverse range of novel therapeutic drug development opportunities. Its patent protected intellectual property in relation to virus infections shows evidence of having wide applications in humans and also in animals – the latter offers the prospect for near term cashflows as testing requirements for animal medicines are less stringent than those for human treatments. We have valued the company on a heavily risk-weighted DCF-based valuation at 4.2p per share and, with the shares trading at 1.85p, this suggests upside potential of over 100%. Any further operational progress, both in terms of drug trials and in the granting of additional licences, will reduce our risk weightings on the product development portfolio and add to that core valuation. On that basis, our stance remains buy at 1.85p.

Hi rthak,a paperloss is just that ,you haven't lost anything till you sell patience will give just rewards....enjoy your travels best of luck